Mitodicure GmbH published a review on Fibromyalgia by Uri Gabbay and Or Carmi proposing skeletal muscle microvascular dysfunction as a core mechanism underlying Fibromyalgia, which converges with research on MECFS and Long COVID.

Public source

Publisher name

Public post

A highly interesting review on #Fibromyalgia by Uri Gabbay and Or Carmi, “Does maladaptive microvascular flow redistribution cause tissue hypoxia in fibromyalgia?”, prop…

Log in to read the full post

Company

About Mitodicure GmbH

Mitodicure’s mission is to cure Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), for which there is no effective treatment. With the founders' decades of experience in drug discovery, we are developing a small molecule drug for this frequent and debilitating disease. Patients with Long COVID and Fibromyalgia could also benefit from our medication. Follow us: https://x.com/mitodicure

See more

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.